End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor

Model‐informed drug development (MIDD) is critical in all stages of the drug‐development process and almost all regulatory submissions for new agents incorporate some form of modeling and simulation. This review describes the MIDD approaches used in the end‐to‐end development of ertugliflozin, a sod...

Descripción completa

Detalles Bibliográficos
Autores principales: Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas K., Callegari, Ernesto, Zhou, Susan, Musante, Cynthia J., Liang, Yali, Sweeney, Kevin, Sahasrabudhe, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213419/
https://www.ncbi.nlm.nih.gov/pubmed/33932126
http://dx.doi.org/10.1002/psp4.12633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213419/
https://www.ncbi.nlm.nih.gov/pubmed/33932126
http://dx.doi.org/10.1002/psp4.12633

Ejemplares similares